Valent BioSciences competitors

Zippia score 4.3

Valent BioSciences main competitors are Ionis Pharmaceuticals, Valent U.S.A, and Chemtura Corp.

Competitor Summary. See how Valent BioSciences compares to its main competitors:

Novozymes has the most employees (6,454).
Employees at Ionis Pharmaceuticals earn more than most of the competitors, with an average yearly salary of $75,204.

Work at Valent BioSciences?

Share your experience

Valent BioSciences vs competitors

Company	Founding date	Zippia score	Headquarters	# of Locations	Revenue	Employees
Valent BioSciences	2000	4.3	Libertyville, IL	1	$35.4M	100
Q-State Biosciences	2013	4.0	Cambridge, MA	1	$425,498	73
Taxon Biosciences, Inc.	-	3.9	Tiburon, CA	1	$1.8M	30
Valent U.S.A	1988	4.8	San Ramon, CA	1	$500.0M	341
Chemtura Corp	2005	4.5	Philadelphia, PA	1	$1.7B	2,500
Surmodics	1979	4.3	Eden Prairie, MN	1	$126.1M	369
Medefil	1998	4.4	Glendale Heights, IL	1	$20.6M	65
Prevalere Life Sciences	2002	4.1	Whitesboro, NY	1	$22.0M	249
IEH	1941	4.2	New York, NY	1	$21.5M	200
Ionis Pharmaceuticals	1989	4.6	Carlsbad, CA	1	$705.1M	817
BioLegend	2002	4.2	San Diego, CA	1	$300.0M	200
Novozymes	1977	4.1	Franklinton, NC	2	$250.0M	6,454
Goulston	1937	4.4	Monroe, NC	1	$30.9M	350
Ciris Energy	2007	3.5	Centennial, CO	1	$630,000	7

Rate Valent BioSciences' competitiveness in the market.

Valent BioSciences salaries vs competitors

Among Valent BioSciences competitors, employees at Ionis Pharmaceuticals earn the most with an average yearly salary of $75,204.

Compare Valent BioSciences salaries vs competitors

Company	Average salary	Hourly salary	Salary score
Valent BioSciences	$51,738	$24.87	-
Q-State Biosciences	$45,948	$22.09	-
Taxon Biosciences, Inc.	$61,506	$29.57	-
Valent U.S.A	$72,901	$35.05	-
Chemtura Corp	$72,482	$34.85	-
Surmodics	$60,440	$29.06	-

Compare Valent BioSciences job title salaries vs competitors

Company	Highest salary	Hourly salary
Valent BioSciences	$83,837	$40.31
Valent U.S.A	$86,163	$41.42
Novozymes	$80,434	$38.67
Chemtura Corp	$77,281	$37.15
Surmodics	$72,035	$34.63
IEH	$72,001	$34.62
Medefil	$71,926	$34.58
Q-State Biosciences	$71,427	$34.34
Goulston	$71,427	$34.34
BioLegend	$70,927	$34.10
Ionis Pharmaceuticals	$70,871	$34.07
Prevalere Life Sciences	$70,772	$34.02
Ciris Energy	$70,748	$34.01
Taxon Biosciences, Inc.	$70,519	$33.90

Do you work at Valent BioSciences?

Is Valent BioSciences able to compete effectively with similar companies?

Valent BioSciences jobs

Valent BioSciences demographics vs competitors

Compare gender at Valent BioSciences vs competitors

Job title	Male	Female
Surmodics	53%	47%
Ionis Pharmaceuticals	57%	43%
Novozymes	59%	41%
IEH	61%	39%
Valent BioSciences	-	-

Male

Female

100%

75%

50%

25%

Valent BioSciences

IEH

Novozymes

Ionis Pharmaceuticals

Surmodics

25%

50%

75%

100%

Compare race at Valent BioSciences vs competitors

Company	White	Hispanic or Latino	Black or African American	Asian	Unknown	Diversity score
Ionis Pharmaceuticals	46%	19%	9%	20%	6%	9.0
Surmodics	61%	11%	10%	13%	6%	7.6
Novozymes	57%	9%	12%	19%	4%	9.6
IEH	62%	16%	11%	8%	3%	9.4

Valent BioSciences and similar companies CEOs

CEOBio

Stanley Crooke

Ionis Pharmaceuticals

Gary R. Maharaj

Surmodics

Gary Maharaj is a Board Member at Faegre & Benson LLP, Board Member at NVE Corp, and President/CEO at SURMODICS INC. He has experience at Smith & Nephew and has worked as President/CEO at Arizant Inc and Vice President at Philip Adam & Assoc. Gary studied at Carlson School of Management, UT Southwestern Medical Center, and University of Texas System.

Ester Baiget

Novozymes

Craig Rogerson

Chemtura Corp

David Offerman

IEH

Dave Offerman is a Chairman/Pres/CEO at IEH Corporation and is based in United States. He has worked as Manager:Natl Sales at IEH Corporation, VP:Sales & Mktg at IEH Corporation, and Board Member at IEH Corporation. Dave attended University of Michigan and New York University.

Gene Lay

BioLegend

Greg G Jenkins

Ciris Energy

Greg Jenkins is a COO at Ciris Energy.

Paul Medeiros

Q-State Biosciences

As Chief Executive Officer of Q-State Biosciences, Paul Medeiros is responsible for overseeing the company’s growth and sharpening its vision. He has nearly 25 years of global executive pharmaceutical experience with an extensive track record of success in biopharma strategy, operations, R&D portfolio and corporate development. Prior to Q-State, Paul served as President and founding executive of Imbrium Therapeutics and directed the company’s business operations and R&D portfolio in the areas of pain and CNS therapeutics. He concurrently served as President of the associated investment/accelerator firm Greenfield BioVentures. In addition to these roles, Paul has fulfilled multiple corporate leadership positions within other biopharmaceutical companies including Mundipharma International in Cambridge UK, AVI BioPharma (now Sarepta Therapeutics), and Schering-Plough Pharmaceuticals. He began his pharma career as an MBA leadership trainee at Merck & Company. Paul has also served on the boards of directors of Praxis Precision Medicines, Kolltan Pharmaceuticals and EDO Pharmaceuticals GMBH. He received his AB with Honors from Brown University and his MBA from Columbia Business School